02383nas a2200397   4500000000100000008004100001260001300042653002300055653001600078653003000094653001200124653003000136653001100166653002300177653001200200653001300212653001300225653002400238100001200262700001500274700001400289700001400303700001500317700001600332700001600348700001500364700001200379700001300391245016400404856005900568300001100627490000700638050003200645520129400677022001401971       1993                            d  c1993 Sep10aBacterial Vaccines10aClofazimine10aCombined Modality Therapy10aDapsone10aDrug Therapy, Combination10aHumans10aLeprostatic Agents10aleprosy10aNeuritis10aRifampin10aSingle-Blind Method1 aKar H K1 aSharma A K1 aMisra R S1 aBeena K R1 aZaheer S A1 aMukherjee R1 aMukherjee A1 aParida S K1 aWalia R1 aNair N S00aReversal reaction in multibacillary leprosy patients following MDT with and without immunotherapy with a candidate for an antileprosy vaccine, Mycobacterium w.  uhttp://leprev.ilsl.br/pdfs/1993/v64n3/pdf/v64n3a05.pdf  a219-260 v64  aInfolep Library - available3 a<p>Immunotherapy with a candidate for an antileprosy vaccine, Mycobacterium w, was given in addition to standard multidrug therapy (MDT) to 53 multibacillary lepromin negative patients belonging to BB, BL and LL types of leprosy (vaccine group). An equal control group received MDT and injections of micronized starch as placebo. Both the vaccine and placebo were administered intradermally every 3 months. The patients were evaluated at determined intervals by clinical, bacteriological and histopathological parameters and lepromin testing. Reactional episodes were analysed with reference to incidence, onset, frequency and severity during and after release from treatment (RFT). Incidence of reversal reaction (RR) was marginally higher in the vaccine group (22.6% vaccine group vs 15% control group). All cases with a history of downgrading type 1 reaction developed RR during therapy. Most episodes occurred within the 1st year of the commencement of therapy--50% developing within 3 months. Late reversal reaction (after RFT) were observed in 3.8% of cases in both groups, and 50% of the reactors in the control group and 33% in the vaccine group had repeated reactional episodes. Incidence of neuritis associated with RR as well as isolated neuritis was similar in both groups.</p>  a0305-7518